Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: A review of current and developing drugs

Expert Opinion on Investigational Drugs

Volumn 24, Issue 12, 2015, Pages 1597-1611

  Mulhall, Aaron M ^a,b   Droege, Christopher A ^a   Ernst, Neil E ^a   Panos, Ralph J ^a,b   Zafar, Muhammad A ^a,b  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

chf6001; chronic obstructive pulmonary disease; gsk256066; phosphodiesterase inhibitor; phosphodiesterase IV; roflumilast; rpl554; tetomilast

Indexed keywords

6 [3 (DIMETHYLCARBAMOYL)PHENYLSULFONYL] 4 (3 METHOXYANILINO) 8 METHYL 3 QUINOLINECARBOXAMIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHF 6001; FORMOTEROL; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV INHIBITOR; ROFLUMILAST; RPL 554; SALMETEROL; TETOMILAST; UNCLASSIFIED DRUG; AMINOPYRIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; CYCLOPROPANE DERIVATIVE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DEPRESSION; DIARRHEA; DRUG BINDING; DRUG EFFICACY; DRUG FORMULATION; DRUG ISOLATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; HUMAN; INSOMNIA; NAUSEA; NONHUMAN; PATIENT CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PHENOTYPE; PHYSICIAN; REVIEW; RHINOPHARYNGITIS; SUICIDAL IDEATION; VOMITING; WEIGHT REDUCTION; ANIMAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; LUNG FUNCTION TEST; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

AMINOPYRIDINES; ANIMALS; BENZAMIDES; BRONCHODILATOR AGENTS; CYCLOPROPANES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS;

EID: 84949209195     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.1094054     Document Type: Review

References (77)

1. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2014.Available from: www.goldcopd.org/guidelines-global-strategy-fordiagnosismanagement. Html
2. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59(7):574-80
3. Spina D. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 2003;63(23):2575-94
4. Page CP, Spina D. Phosphodiesterase inhibitors in the treatment of inflammatory diseases. Handb Exp Pharmacol 2011;204:391-414
5. Maurice DH, Ke H, Ahmad F, et al. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 2014;13(4):290-314
6. Giembycz MA, Maurice DH. Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease. Curr Opin Pharmacol 2014;16:89-107
7. Boswell-Smith V, Spina D. PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast. Int J Chron Obstruct Pulmon Dis 2007;2(2):121-9
8. Food and Drug Administration. Pulmonary-allergy drugs advisory committee. NDA 22-522: Daxas (roflumilast 500 μg tablets). 2011.Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM207377.pdf
9. Vignola AM. PDE4 inhibitors in COPD - a more selective approach to treatment. Respir Med 2004;98(6):495-503
10. Soto FJ, Hanania NA. Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease. Curr Opin Pulm Med 2005;11(2):129-34
11. Profita M, Chiappara G, Mirabella F, et al. Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD. Thorax 2003;58(7):573-9
12. Selige J, Tenor H, Hatzelmann A, Dunkern T. Cytokine-dependent balance of mitogenic effects in primary human lung fibroblasts related to cyclic AMP signaling and phosphodiesterase 4 inhibition. J Cell Physiol 2010;223(2):317-12
13. Daxas: EPAR-Product Information. 2010.Available from: www ema.europa. eu/docs/en-GB/document-library/EPAR - -Product- Information/human/001179/WC500095209.pdf
14. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009;374(9691):695-703
15. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374(9691):685-94
16. Martinez FJ, Calverley PM, Goehring UM, et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 2015;385(9971):857-66
17. Rabe KF, Bateman ED, O'Donnell D, et al. Roflumilast-an oral antiinflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366(9485):563-71
18. Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176(2):154-61
19. Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013;11:CD002309
20. Zafar MA, Droege C, Foertsch M, Panos RJ. Update on ultra-long-acting beta agonists in chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2014;23(12):1687-701
21. Rennard SI, Calverley PM, Goehring UM, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. Respir Res 2011;12:18
22. Wedzicha JA, Rabe KF, Martinez FJ, et al. Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest 2013;143(5):1302-11
23. Fu JJ, Gibson PG, Simpson JL, McDonald VM. Longitudinal changes in clinical outcomes in older patients with asthma, COPD and asthma-COPD overlap syndrome. Respiration 2014;87(1):63-74
24. Bundschuh DS, Eltze M, Barsig J, et al. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001;297(1):280-90
25. Martinez FJ. Roflumilast: clinical review of a new option for the treatment of inflammation in COPD. Arch Bronconeumol 2010;46(Suppl 9):8-11
26. Wouters EF, Bredenbroker D, Teichmann P, et al. Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. J Clin Endocrinol Metab 2012;97(9):E1720-5
27. Francis S, Conti M, Houslay M. Handbook of Experimental Pharmacology Volume 204. Phosphodiesterases as Drug Targets. Springer-Verlag Berlin Heidelberg; London: 2011
28. Mallikaarjun S, Shoaf S, Zhang P, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of tetomilast in stable COPD subjects. Eur Respir J 006:661S-P3838
29. Pilot study of tetomilast in chronic obstructive pulmonary disease (COPD) Associated With Emphysema (EMPHASIS). 2015.Available from: https://clinicaltrials.gov/ct2/show/NCT00874497? term=NCT00874497&rank=1
30. To investigate the efficacy and safety of OPC-6535 in chronic obstructive pulmonary disease (COPD) Patients. 2014.Available from: https://clinicaltrials.gov/ct2/show/NCT00917150? term=00917150&rank=1
31. Schreiber S, Keshavarzian A, Isaacs KL, et al. A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology 2007;132(1):76-86
32. Nials AT, Tralau-Stewart CJ, Gascoigne MH, et al. In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther 2011;337(1):137-44
33. Tralau-Stewart CJ, Williamson RA, Nials AT, et al. GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization. J Pharmacol Exp Ther 2011;337(1):145-54
34. Watz H, Mistry SJ, Lazaar AL; IPC101939 investigators. Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD. Pulm Pharmacol Ther 2013;26(5):588-95
35. A study to evaluate the efficacy after allergen challenge, safety and tolerability of inhaled CHF6001 DPI in asthmatics (CHF6001-POC2). 2013.Available from: https://clinicaltrials.gov/ct2/show/NCT01689571? term=01689571&rank=1
36. Study to investigate the pharmacokinetics of chf 6001 dpi administered via nexthaler-device or the capsule for oral inhalation via aerolizer-device. 2014.Available from: https://clinicaltrials.gov/ct2/show/NCT02119247? term=02119247&rank=1
37. Safety, tolerability and efficacy of 28-day inhaled chf 6001 dpi in copd patients. 2014.Available from: https://clinicaltrials.gov/ct2/show/NCT01730404? term=01730404&rank=1
38. A study to investigate the safety, tolerability and pharmacokinetics of inhaled chf6001 (chf6001Ext). 2015.Available from: https://clinicaltrials.gov/ct2/show/NCT02386761? term=02386761&rank=1
39. Moretto N, Caruso P, Bosco R, et al. CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration. J Pharmacol Exp Ther 2015;352(3):559-67
40. Villetti G, Carnini C, Battipaglia L, et al. CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration-in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window. J Pharmacol Exp Ther 2015;352(3):568-78
41. Esposito O, Mariotti M, Acerbi D, et al. Safety, tolerability and pharmacokinetics of a new inhaled once-daily phosphodiesterase (PDE) 4 inhibitor in healthy volunteers. Eur Respir Soc Ann Congress 2013
42. Franciosi LG, Diamant Z, Banner KH, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med 2013;1(9):714-27
43. Comparison of RPL554 with placebo and salbutamol in asthmatic patients [Internet]. 2015;Available from: https://clinicaltrials.gov/ct2/show/NCT02427165? term=02427165&rank=1
44. SAD/MAD study of a new formulation of nebulised RPL554 in healthy subjects and COPD subjects. 2015.Available from: https://clinicaltrials.gov/ct2/show/NCT02307162? term=02307162&rank=1
45. Boswell-Smith V, Spina D, Oxford AW, et al. The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2 (2,4,6-trimethylphenylimino)-3-(ncarbamoyl-2-aminoethyl)-3,4,6, 7-tetrahydro-2H-pyrimido[6,1-a] isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquino lin-4-one. J Pharmacol Exp Ther 2006;318(2):840-8
46. Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000;161(1):309-29
47. Calzetta L, Cazzola M, Paige CP, et al. Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. Pulm Pharmacol Ther 2015;32:15-23
48. Rocco PR, Momesso DP, Figueira RC, et al. Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury. Eur Respir J 2003;22(1):20-7
49. Kita T, Fujimura M, Myou S, et al. Effects of KF19514, a phosphodiesterase 4 and 1 Inhibitor, on bronchial inflammation and remodeling in a murine model of chronic asthma. Allergol Int 2009;58(2):267-75
50. Provins L, Christophe B, Danhaive P, et al. Dual M3 antagonists-PDE4 inhibitors. Part 2: Synthesis and SAR of 3-substituted azetidinyl derivatives. Bioorg Med Chem Lett 2007;17(11):3077-80
51. Tannheimer SL, Sorensen EA, et al. The in vitro pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting beta2-adrenoceptor agonist. J Pharmacol Exp Ther 2014;349(1):85-93
52. Liu A, Huang L, Wang Z, et al. Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: dual beta(2)-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD. Bioorg Med Chem Lett 2013;23(5):1548-52
53. Huang L, Shan W, Zhou Q, et al. Design, synthesis and evaluation of dual pharmacology beta2-adrenoceptor agonists and PDE4 inhibitors. Bioorg Med Chem Lett 2014;24(1):249-53
54. Kubo S, Kobayashi M, Iwata M, et al. Disease-modifying effect of ASP3258, a novel phosphodiesterase type 4 inhibitor, on subchronic cigarette smoke exposureinduced lung injury in guinea pigs. Eur J Pharmacol 2011;659(1):79-84
55. Kubo S, Kobayashi M, Iwata M, et al. Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor. Int Immunopharmacol 2012;12(1):59-63
56. Kobayashi M, Kubo S, Hirano Y, et al. Anti-asthmatic effect of ASP3258, a novel phosphodiesterase 4 inhibitor. Int Immunopharmacol 2012;12(1):50-8
57. Kobayashi M, Kubo S, Iwata M, et al. ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity. Int Immunopharmacol 2011;11(6):732-9
58. Chapman R, House A, Richard J, et al. Pharmacology Of SCH900182, A Potent, Selective Inhibitor Of PDE4 For Inhaled Administration. Am J Respir Crit Care Med 2010;181:A5671
59. Kwak HJ, Nam JY, Song JS, et al. Discovery of a novel orally active PDE-4 inhibitor effective in an ovalbumininduced asthma murine model. Eur J Pharmacol 2012;685(1-3):141-8
60. Yougbare I, Morin C, Senouvo FY, et al. NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues. Am J Physiol Lung Cell Mol Physiol 2011;301(4):L441-50
61. Campos HS, Xisto DG, Oliveira MB, et al. Protective effects of phosphodiesterase inhibitors on lung function and remodeling in a murine model of chronic asthma. Braz J Med Biol Res 2006;39(2):283-7
62. Manabe H, Akuta K, Kawasaki H, Ohmori K. The inhaled administration of KF19514, a phosphodiesterase 4 and 1 inhibitor, prevents antigen-induced lung inflammation in guinea pigs. Pulm Pharmacol Ther 2000;13(1):5-11
63. Myou S, Fujimura M, Kurashima K, et al. Effect of aerosolized administration of KF19514, a phosphodiesterase 4 inhibitor, on bronchial hyperresponsiveness and airway inflammation induced by antigen inhalation in guinea-pigs. Clin Exp Allergy 2000;30(5):713-18
64. Salmon M, Tannheimer SL, Gentzler TT, et al. The in vivo efficacy and side effect pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long-acting beta 2-adrenoceptor agonist in preclinical animal species. Pharmacol Res Perspect 2014;2(4):e00046
65. Barr RG, Rowe BH, Camargo CA. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. BMJ 2003;327(7416):643
66. Ram FS, Jones PW, Castro AA, et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002(4):CD003902
67. Aubier M. Effect of theophylline on diaphragmatic muscle function. Chest 1987;92(1 Suppl):27S-31S
68. Barnes PJ. Theophylline. Am J Respir Crit Care Med 2013;188(8):901-6
69. Devereux G, Cotton S, Barnes P, et al. Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial. Trials 2015;16:267
70. Rivington RN, Calcutt L, Hodder RV, et al. Safety and efficacy of once-daily Uniphyl tablets compared with twicedaily Theo-Dur tablets in elderly patients with chronic airflow obstruction. Am J Med 1988;85(1B):48-53
71. Nishimura K, Koyama H, Ikeda A, et al. The additive effect of theophylline on a high-dose combination of inhaled salbutamol and ipratropium bromide in stable COPD. Chest 1995;107(3):718-23
72. Zhou Y, Wang X, Zeng X, et al. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebocontrolled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology 2006;11(5):603-10
73. Ni W, Shao X, Cai X, et al. Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a metaanalysis. PLoS ONE 2015;10(3):e0121257
74. Diamant Z, Spina D. PDE4-inhibitors: a novel, targeted therapy for obstructive airway disease. Pulm Pharmacol Ther 2011;24(4):353-60
75. Burgin AB, Magnusson OT, Singh J, et al. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol 2010;28(1):63-70
76. Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 2009;8(1):41-54
77. Altucci L, Leibowitz MD, Ogilvie KM, et al. RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 2007;6(10):793-810